U.S. Food and Drug Administration

By David Miller Seattle Genetics dodged the bullet, but who might be next? And how do investors know when a report is something to worry about? A few years back, the Food and Drug Administration (FDA) created the Adverse Events Reporting System or AERS. Reporting to the system is voluntary for...

Best 1) Southern Union (NYSE: SUG): Shares of Southern Union are currently trading up 16.4% from yesterday's close to $39.76. The company has received an acquisition proposal from The Williams Companies (NYSE: WMB) for $39 per share in cash. The deal is valued at 8.7 billion. Southern Union...

Best 1) Southern Union (NYSE: SUG): Shares of Southern Union are currently trading up 16.9% from yesterday's close to $39.93. The company has received an acquisition proposal from The Williams Companies (NYSE: WMB) for $39 per share in cash. The deal is valued at 8.7 billion. Southern Union...

Best 1) Hollysys Automation Technologies (NASDAQ: HOLI): Shares of Hollysys Automation Technologies are currently trading down 14.8% from yesterday's close to $11.12. The stock started the session in negative territory, but heavy buying volume began to push shares up starting at 9:54am. 2) DST...

Best 1) Fonar (NASDAQ: FONR): Trading up 27.3% from yesterday's close to $2.77. Fonar reported a 15% increase in revenue to $8.7 million for the third quarter. Net income came in at $0.20 per share versus $7.5 million for the same period last year. Shares set a new 52-week high of $3.20 earlier in...

Best 1) Fonar (NASDAQ: FONR): Trading up 25.1% from yesterday's close to $2.72. Fonar reported a 15% increase in revenue to $8.7 million for the third quarter. Net income came in at $0.20 per share versus $7.5 million for the same period last year. Shares set a new 52-week high of $3.20 earlier in...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec (Nasdaq: BIIB) today announced the U.S. Food and Drug Administration (FDA) approved Rituxan® (rituximab) as a maintenance treatment for patients with advanced follicular lymphoma who responded to initial treatment...

Shares of Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) are currently up 19.1% at $6.75 per share during Friday afternoon trading. The company's share price soared after it announced on Thursday after the market closed that it received approval from the U.S. Food and Drug Administration (FDA) for...

Shares of pSivida Corp. (Nasdaq: PSDV) are currently down 20.1% at $5.08 per share during Monday afternoon trading. pSivida Corporation reported after the market closed on Thursday that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New...

Shares of Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) ended the Wednesday trading session down 10.9% at $6.15 per share. Cumberland Pharmaceuticals Inc announced on Wednesday before the market opened that it had received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration...